Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Sacituzumab Govitecan Meets Primary End Point in Phase 3 ASCENT Trial

July 6th 2020

The novel antibody-drug conjugate sacituzumab govitecan-hziy demonstrated significant improvement in survival in patients with triple-negative breast cancer without brain metastases who previously received at least 2 prior therapies for metastatic disease.

Expert Highlights Unmet Need for Patients With Metastatic HER2+ Breast Cancer and Brain Metastases

July 6th 2020

Brian Czerniecki, MD, PhD, discusses how patients with metastatic HER2-positive breast cancer who later develop central nervous system metastases comprise a large population of all patients with breast cancer, and there continue to be an unmet need for this subgroup.

Dr. Adams on the Utility of Combination CTLA-4 and PD-1 Blockade in Breast Cancer

July 6th 2020

Sylvia Adams, MD, discusses the utility of combining anti–CTLA-4 and anti–PD-1 agents in breast cancer.

Next Generation of Combo Regimens Being Explored in ER+ Breast Cancer

July 2nd 2020

Hung Khong, MD, discusses the potential to combine endocrine therapy with immunotherapy in patients with ER-positive breast cancer, and other intriguing therapies poised to improve transform the pipeline.

The Benefits of Tucatinib in HER2+ Breast Cancer

July 1st 2020

Understanding the HER2CLIMB Trial

July 1st 2020

A Close Look at Tucatinib in HER+ Breast Cancer

July 1st 2020

Treatment for Metastatic Breast Cancer

July 1st 2020

Impact of Recent Clinical Data on Treatment for HER2+ MBC

June 30th 2020

CDK4/6 Inhibitors for Triple-Positive Breast Cancer

June 30th 2020

SOPHIA: Margetuximab + Chemotherapy for RR HER2+ MBC

June 30th 2020

DS-8201 and Tucatinib in HER2+ Metastatic Breast Cancer

June 30th 2020

Treatment Choice for Patient Relapsing With Brain Metastases

June 30th 2020

HER2CLIMB: Brain Metastases Data

June 30th 2020

Biomarker Data After Neoadjuvant Therapy for HER2+ Breast Cancer

June 30th 2020

HER2+ Early Stage Breast Cancer With Residual Invasive Disease

June 30th 2020

KAITLIN: T-DM1/Pertuzumab After Anthracycline-Based Adjuvant Therapy

June 30th 2020

TRAIN-2: Anthracyclines in HER2+ Breast Cancer

June 30th 2020

APHINITY and ExteNET Trials for Early-Stage Breast Cancer

June 30th 2020

HER2+ Early-Stage Breast Cancer

June 30th 2020